1/6
08:30 am
srpt
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/31
04:10 pm
srpt
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/30
10:38 am
srpt
High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]
12/22
10:19 pm
srpt
High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]
12/20
06:32 am
srpt
High Growth Tech Stocks To Watch For Potential Opportunities [Yahoo! Finance]
Low
Report
High Growth Tech Stocks To Watch For Potential Opportunities [Yahoo! Finance]
12/20
05:21 am
srpt
High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]
12/20
04:25 am
srpt
High Growth Tech And 2 Other Promising Stocks With Strong Potential [Yahoo! Finance]
Low
Report
High Growth Tech And 2 Other Promising Stocks With Strong Potential [Yahoo! Finance]
12/19
10:12 am
srpt
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder [Yahoo! Finance]
Low
Report
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder [Yahoo! Finance]
12/19
08:10 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "sell" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "sell" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
12/18
08:36 am
srpt
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 [Yahoo! Finance]
Medium
Report
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 [Yahoo! Finance]
12/18
08:30 am
srpt
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Medium
Report
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
12/17
10:30 am
srpt
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 [Yahoo! Finance]
Low
Report
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 [Yahoo! Finance]
12/16
01:27 am
srpt
High Growth Tech And 2 Other Promising Stocks To Watch [Yahoo! Finance]
Medium
Report
High Growth Tech And 2 Other Promising Stocks To Watch [Yahoo! Finance]
12/15
09:32 pm
srpt
Exploring Three High Growth Tech Stocks With Promising Potential [Yahoo! Finance]
Medium
Report
Exploring Three High Growth Tech Stocks With Promising Potential [Yahoo! Finance]
12/15
09:32 pm
srpt
High Growth Tech Stocks Including Park Systems And Two Others [Yahoo! Finance]
Medium
Report
High Growth Tech Stocks Including Park Systems And Two Others [Yahoo! Finance]
12/9
12:29 pm
srpt
High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]
12/9
10:27 am
srpt
High Growth Tech Stocks And 2 Other Promising Tech Companies [Yahoo! Finance]
Low
Report
High Growth Tech Stocks And 2 Other Promising Tech Companies [Yahoo! Finance]
12/9
08:24 am
srpt
High Growth Tech Stocks to Watch in December 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks to Watch in December 2024 [Yahoo! Finance]
12/9
04:15 am
srpt
Exploring High Growth Tech Stocks In December 2024 [Yahoo! Finance]
Low
Report
Exploring High Growth Tech Stocks In December 2024 [Yahoo! Finance]
12/6
08:30 am
srpt
High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]
12/3
09:02 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at HC Wainwright from $80.00 to $75.00. They now have a "sell" rating on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at HC Wainwright from $80.00 to $75.00. They now have a "sell" rating on the stock.
11/29
04:10 pm
srpt
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/29
03:58 pm
srpt
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock? [Yahoo! Finance]
Neutral
Report
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock? [Yahoo! Finance]
11/29
11:32 am
srpt
High Growth Tech Stocks To Explore This November 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks To Explore This November 2024 [Yahoo! Finance]
11/29
10:32 am
srpt
High Growth Tech Stocks None Leads These 3 Promising Picks [Yahoo! Finance]
Low
Report
High Growth Tech Stocks None Leads These 3 Promising Picks [Yahoo! Finance]